Clinical Study
Safety and Tolerability of Antiretrovirals during Pregnancy

Adriana Weinberg, Jeri Forster-Harwood, Jill Davies, Elizabeth J. McFarland, Jennifer Pappas, Kay Kinzie, Emily Barr, Suzanne Paul, Carol Salbenblatt, Elizabeth Soda, Anna Vazquez, and Myron J. Levin

1 School of Medicine University of Colorado Denver, Research Complex 2, Mail Stop 8604, 12700 E. 19th Avenue, Aurora, CO 80045, USA
2 Department of Obstetrics and Gynecology, University of Colorado Hospital, Aurora, CO 80045, USA
3 Pediatric Infectious Diseases, The Children's Hospital, Aurora, CO, USA

Correspondence should be addressed to Adriana Weinberg, adriana.weinberg@ucdenver.edu

Received 8 December 2010; Revised 3 February 2011; Accepted 17 February 2011

Academic Editor: Michael G. Gravett

Copyright © 2011 Adriana Weinberg et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Combination antiretroviral therapy (CART) dramatically decreases mother-to-child HIV-1 transmission (MTCT), but maternal adverse events are not infrequent. A review of 117 locally followed pregnancies revealed 7 grade ≥3 AEs possibly related to antiretrovirals, including 2 hematologic, 3 hepatic, and 2 obstetric cholestasis cases. A fetal demise was attributed to obstetric cholestasis, but no maternal deaths occurred. The drugs possibly associated with these AE were zidovudine, nelfinavir, lopinavir/ritonavir, and indinavir. AE or intolerability required discontinuation/substitution of nevirapine in 16% of the users, zidovudine in 10%, nelfinavir in 9%, lopinavir/ritonavir in 1%, but epivir and stavudine in none. In conclusion, nevirapine, zidovudine, and nelfinavir had the highest frequency of AE and/or the lowest tolerability during pregnancy. Although nevirapine and nelfinavir are infrequently used in pregnancy at present, zidovudine is included in most MTCT preventative regimens. Our data emphasize the need to revise the treatment recommendations for pregnant women to include safer and better-tolerated drugs.

1. Introduction

Combination antiretroviral therapy (CART) has decreased HIV mother-to-child-transmission (MTCT) to <2% in the USA and other countries where ART is readily available [1–5]. To reliably achieve suppression of maternal HIV replication, which is essential for prevention of MTCT, information on the safety and tolerability of drug regimens for HIV-infected pregnant women is critically important.

Antiretroviral regimens recommended by the WHO for PMTCT (http://www.who.int/hiv/pub/mtct/antiretroviral2010/en/index.html) include zidovudine (AZT) and lamivudine (3TC) with a single dose of nevirapine (NVP) at delivery or AZT/3TC with lopinavir/ritonavir (LPV/RTV), with efavirenz (EFV; only in the 2nd trimester or later) or with abacavir (ABC) for the entire duration of treatment in pregnancy. Overall, the most commonly used nucleoside reverse transcriptase inhibitors (NRTIs) during pregnancy are AZT and 3TC [6]. Some NRTIs are avoided during pregnancy due to their toxicity, such as didanosine (DDI) with stavudine (D4T) [7]. NVP was associated in some studies with a high level of hepatotoxicity in women with CD4 > 200 cells/µL [8, 9]. Although this observation was not confirmed in other studies [10, 11], NVP is currently recommended only as a single dose at delivery or in women with CD4 < 250 cells/µL. Tenofovir (TNV) has not been extensively studied in pregnancy. Its use is limited because of its effect on bone mineralization [12, 13].

Although CART for the mother clearly reduces the risk of HIV MTCT, it is not universally used for this purpose because of the high cost of drugs, concern with the safety and tolerability of different classes of antiretrovirals [14–19] and with the potential emergence of drug resistance in mothers who stop CART after delivery [20–23]. In a previous study, we showed that the use of CART by 117 women in our clinic during pregnancy was not associated with drug resistance [24]. This was subsequently confirmed by similar findings in other studies [25].
The objective of this study was to evaluate the safety and tolerability of different components of CART during pregnancy.

2. Material and Methods

2.1. Study Design. This was a retrospective chart review study of CART utilization and adverse events (AEs) in pregnancies managed by the Children’s Human Immunodeficiency Program (CHIP) in Denver, Colo between August 1997 and December 2005, as previously described [26]. Basic CART consisted of ≥3 ARV representing ≥2 classes. Hematology, chemistry, and liver function tests were done at 4- to 8-week intervals. For this report, we collected and analyzed AE for pregnancies of at least 16 weeks duration and with at least 2 visits to CHIP and drug substitutions due to grade ≥3A or intolerance of ART, defined as inability to tolerate nonlife threatening clinical AEs, such as headache, nausea, diarrhea, or other subjective disorders. AEs were classified as per the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, dated December, 2004 (http://rcc.tech-res.com/safetyandpharmacovigilance/).

2.2. Statistical Analyses. We utilized a two-sided test of hypothesis with a significance level of 0.05, and it was performed in SAS v9.2. Characteristics are presented as medians with interquartile ranges or number (N) and percent in a category, as appropriate. McNemar’s test was used to assess whether AZT and D4T were more likely to be added versus discontinued during pregnancy.

3. Results

3.1. Demographics and HIV-Disease Characteristics. Of 124 pregnancies that met inclusion criteria, complete medical records were available on 117 pregnancies including 12 women with 2 pregnancies (Table 1). Median gestational age at delivery was 38 weeks (interquartile range (IQR) = 37–40 weeks). Of 120 infants (3 twin gestations), 2 were still-born, 1 died of sepsis at 1 day of life, and 117 survived and were free of HIV.

3.2. Antiretrovirals and AEs during Pregnancy. The median duration of continuous therapy during pregnancy was 22 weeks (IQR = 15–35 weeks). Among 115 evaluable women at delivery, 106 (94%) were on CART ≥3 drugs from ≥2 classes; 7 women (4%) were on 2 or 3 NRTI due to lack of tolerance of CART; 1 woman was on AZT monotherapy, and 1 woman refused ART. Hematologic, metabolic, hepatic, and pancreatic AEs identified by routine testing were confirmed by repeat testing (Table 2). Grade ≥3 anemia was documented in 2 patients (2%), one of whom also had thrombocytopenia. Both women were receiving AZT when hematologic abnormalities developed. Laboratory values improved after AZT discontinuation suggesting that AZT caused the SAE. Five additional subjects, including 4 on AZT, had grade 1 or 2 hematologic AEs.

There were 4 grade ≥3 hepatobiliary SAE in 3 of 99 evaluable women (3%), including one with 2 pregnancies. Two women had underlying liver disease caused by hepatitis C virus or hepatic steatosis. The drugs deemed probably responsible for the SAE were ritonavir- (RTV-) boosted saquinavir (SAQ), indinavir (IDV), nelfinavir (NFV), and AZT. Fifteen pregnancies (15%) were complicated by grade 1 or 2 liver function abnormalities, none of which required ARV changes.

Of 69 women with amylase measurements, 3 (4%) had grade 1 or 2 transient elevations, which normalized without any intervention and, therefore, could not be ascribed to ARV.

Two women were diagnosed with obstetric cholestasis (OC) defined by pruritic rash and elevated bile acids. One of them with chronic hepatitis C infection had a nonviable fetus at the time of OC diagnosis. The other individual without underlying liver disease delivered a healthy infant by Cesarean section. Both individuals were on PI-containing...
Table 2: Laboratory adverse events.

| Adverse event          | N tested* | Grades 4* | Grades 3* | Grades 2* | Grades 1* |
|------------------------|-----------|-----------|-----------|-----------|-----------|
| Anemia                 | 110       | 2 (2%)    | 0         | 1 (1%)    | 4 (4%)    |
| Thrombocytopenia       | 110       | 0         | 1 (1%)    | 0         | 2 (2%)    |
| Neutropenia            | 110       | 0         | 0         | 3 (3%)    | 1 (1%)    |
| Elevated ALT           | 98        | 1 (1%)    | 1 (1%)    | 4 (4%)    | 6 (6%)    |
| Elevated AST           | 99        | 0         | 2 (2%)    | 4 (4%)    | 8 (8%)    |
| Elevated bilirubin     | 98        | 0         | 0         | 1 (1%)    | 2 (2%)    |
| Elevated alkaline phosphatase | 96 | 0 | 0 | 2 (2%) | 17 (18%) |
| Elevated amylase       | 69        | 0         | 0         | 2 (3%)    | 1 (1%)    |

*AE grades are the maximum observed grade for each pregnancy. Grading was performed according to the Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 1.0, dated December 2004 (http://rcc.tech-res.com/safetyandpharmacovigilance/).

Table 3: Drug substitutions or discontinuations during pregnancy.

| Class | Drug | N events/N pregnancies | Percent (95% confidence interval) |
|-------|------|------------------------|----------------------------------|
| NRTI  | AZT  | 10/99                  | 10 (5–18)                        |
|       | 3TC  | 0/109                  | 0 (0–3)                          |
|       | d4T  | 0/23                   | 0 (0–15)                         |
|       | ABC  | 1/8                    | 13 (0–53)                        |
|       | ddI  | 0/6                    | 0 (0–46)                         |
|       | TDF  | 0/2                    | 0 (0–84)                         |
|       | FTC  | 0/1                    | 0 (0–98)                         |
| NNRTI | NVP  | 3/19                   | 15 (3–38)                        |
|       | DLV  | 0/1                    | 0 (0–98)                         |
|       | EFV  | 2/2                    | n.a.                             |
| PI    | NFV  | 6/64                   | 9 (4–19)                         |
|       | LPV/RTV | 2/28               | 1 (1–24)                         |
|       | IDV  | 0/5                    | 0 (0–60)                         |
|       | IDV/RTV | 0/1               | 0 (0–98)                         |
|       | SQV  | 0/2                    | 0 (0–84)                         |
|       | SQV/RTV | 2/9                | 22 (3–60)                        |

*Excludes EFV substitutions.

In the drug class summary, a pregnancy in which ≥2 drugs from the same class were substituted was counted only once.

regimens at the time OC was diagnosed: one on NFV and one on lopinavir (LPV) with RTV boost. The patient with underlying hepatitis C had a subsequent pregnancy, during which she received a triple NRTI regimen (AZT/3TC/ABC). She did not develop OC and delivered a healthy, uninfected infant.

Two women developed rashes while on NVP, which improved after NVP discontinuation. There were other clinical AE, including nausea, vomiting, diarrhea, perioral paresthesias, headache, and insomnia that prompted drug discontinuations.

3.3. Changes in ART Caused by ARV Intolerance during Pregnancy. Grade ≥3 AE or poor tolerability prompted 17 changes in therapy in 16 out of 117 pregnancies (14%; Table 3).

There were 11 NRTI substitutions in 114 women receiving NRTI (10%). Ten involved AZT and were due to hematologic SAE, progressive anemia, which in the opinion of the health care provider would reach grade ≥3 before the end of pregnancy, headache, insomnia, or gastric discomfort. Overall, AZT was more likely to be discontinued than added \((P = .004, \text{McNemar’s test})\). AZT was most commonly substituted by D4T, which was more likely to be added than discontinued \((P = .02, \text{McNemar’s test})\). The average durations of AZT and D4T therapy during pregnancy were similar at 140 and 111 days, respectively \((SD = 83 \text{ and } 73, \text{resp.})\).

NNRTI substitutions occurred in 3 of 21 women (14%) receiving NNRTI other than efavirenz (EFV). All occurred among 19 women on NVP. EFV was substituted in 2 women who inadvertently became pregnant while on EFV. Their infants did not have any gross abnormalities at birth or during follow-up.

PI substitutions occurred in 8 of 97 pregnancies (8%) with PI-containing CART. LPV/RTV and NFV were the PI most commonly administered. LPV/RTV was used in 28 pregnancies and was substituted or discontinued due to toxicity or lack of tolerability in 2 women (1%). NFV was substituted in 6 (9%) of 64 women. Other PIs, such as saquinavir and indinavir, were less commonly used.

4. Discussion

In this study, 8% of pregnancies were complicated by grade ≥3 AE probably or possibly due to ARV which is similar to previous reports \([27–29]\). SAE probably or possibly related to the use of ARV included 3 hematologic, 4 hepatic, and
2 OC. One woman had multiple SAE during 2 pregnancies. The incidence of ARV-associated SAE and the rate of drug substitutions did not significantly differ across classes of drugs, suggesting that they were equally safe and well tolerated during pregnancy.

Among NRTI, AZT was the most poorly tolerated drug. In the first AZT trial for PMTCT [30], the incidence of AE in mothers receiving AZT monotherapy was similar to that in placebo recipients. However, HIV replication was poorly controlled in that study and may have contributed to the overall incidence of AE. Other studies using combination therapy during pregnancy showed frequent hematologic toxicities in mothers and children who received AZT [27, 31–33]. In our study, although mothers who developed hematologic SAE ascribed to AZT were receiving combination ART at the time of the event, laboratory values improved after AZT substitution, suggesting that AZT was responsible for the AE. Despite its marginal safety and tolerability during pregnancy, AZT is the main drug recommended by USPHS and WHO for PMTCT. This is partly due to the reluctance to substitute a drug with proven efficacy. However, CART has higher or equal efficacy for PMTCT than AZT alone, making it possible to substitute AZT with other drugs to avoid undesirable side effects.

Drugs that could potentially substitute AZT in combination ART for PMTCT are TTV, ABC, and D4T, all of which synergize with 3TC. The Antiretroviral Pregnancy Drug Registry includes data on ≥628 pregnancies for each of these drugs with a rate of congenital birth defects similar to that of the general population [6]. Although these drugs appear nonteratogenic, they face other limitations. TTV interferes with bone formation in experimental animals [13]. In small numbers of reports in humans, results were variable [34, 35], and, therefore, providers tend to avoid TTV in pregnancy. The use of ABC is limited by its potential allergic reactions. This risk can be mitigated by HLA B5701 detection, which defines the likelihood of ABC hypersensitivity [36]. In pregnancy, drug changes have to be quickly implemented, which may not be compatible with the delay required for HLA typing. Finally, D4T has been associated with peripheral neuropathy, lactic acidosis and other metabolic abnormalities including lipodystrophy [37, 38]. Nevertheless, this drug continues to be widely used in resource-limited countries. In our experience, D4T administered for a limited period of time during pregnancy was well tolerated. The average duration of treatment with D4T and AZT were similar in this study, but patients did not have to discontinue D4T during pregnancy. These findings are consistent with other studies that showed a lower rate of substitution of D4T compared to AZT in nonpregnant adults [39, 40]. Furthermore, D4T crosses the placenta and achieves sufficient levels in the fetus for pre-exposure prophylaxis. Although based on a limited number of observations (N = 23), our data suggest that D4T may be a viable alternative to AZT during pregnancy.

NNRTI are uncommonly used during pregnancy other than single-dose NVP at delivery. EFV is contraindicated in the first trimester due to its potential teratogenicity [41]. EFV has recently been included in the WHO recommendations for combination ART after ≥14 weeks of gestation, but its use is still limited. Delavirdine and etravirine have been insufficiently studied during pregnancy. NVP, which was widely used for PMTCT in the late 1990s, is currently contraindicated in pregnant women with ≥250 CD4 cells/μL due to potential hepatic and cutaneous toxicity. In this study, NVP was used in 19 women with a median first visit CD4 of 419 (IQR = 205–588). Three (16%) required NVP substitution due to mild or moderate AE.

NFV, the PI most commonly used in this study was poorly tolerated in 6 of 64 women (9%). The second most commonly used PI was LPV/RTV, which was well tolerated by 26 of 28 women. Three women developed 4 episodes of grade ≥3 hepatic AE, 3 of which were associated with PI (NFV, SAQ/RTV and indinavir). In addition, two cases of OC were diagnosed in women receiving PI. The relationship between OC and ARV is not clear. The ARV Registry includes very few episodes of OC, but the registry, which was designed for birth defects, does not systematically collect other AE, which may underestimate their incidence, including OC. OC resulting from a pregnancy-specific accumulation of bile acids is associated with fetal demise [42]. The risk of OC is increased by chronic hepatitis C infection [43], which was present in one of our study women, and by other chronic liver conditions. Otherwise, OC is quite uncommon in Europeans, with an incidence of 0.1 to 2%, but quite common in Chile (9 to 16%), possibly related to the genetic background of the population [44, 45]. PI and other ARV have hepatotoxic potential [11, 46] that may contribute to OC. This hypothesis deserves to be further studied.

In conclusion, the safety and tolerability of CART in pregnancy did not differ by class of ARV, but there were differences among individual drugs. Drugs with the poorest safety and tolerability were AZT, NVP, and NFV. Our findings support the need to devise new CART regimens for PMTCT that will avoid the use of poorly tolerated drugs.

Acknowledgments

The authors thank Dr. H Watts, MD, for critical review of the paper and the following providers for referring their patients to our service: L Anneberg, MD; B Barber, NP; C Benson, MD; W Burman, MD; W Callan, MD; P Caraway, NP; M Carten, MD; A Davis, MD; J DesJardin, MD; A Dullit, MD; C Fisher, MD; R Gass, MD; D Guinn, MD; W Hoppe, MD; S Johnson, MD; D Kronbach, MD; C Kurwola, MD; N Madinger, MD; S Mason, MD; L McLaughlan, MD; R Peskind, MD; H Puget, MD; K Rowley, MD; M Schulte, MD; M Schwarz, MD; J Sheppard, MD; J Shlay, MD; B St. Dennis, RN; D Stark, MD; C Steinberg, MD; C Stevens MD; D Strandberg, MD; D Urioste, MD; W Williams, MD; M Winslow, MD; T Yettern NP; B Young, MD. This research was supported by research grants from Abbott Laboratories, Inc. and from Pfizer, Inc. The Children’s Hospital Immunodeficiency Program (CHIP) has funding from Ryan White title IV (2H12HA0070-07 to M. J. Levin) and NICHD (U0132915-05 to M. J. Levin).
References

[1] C. Thorne, “Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy,” Clinical Infectious Diseases, vol. 40, no. 3, pp. 458–465, 2005.

[2] C. L. Townsend, M. Cortina-Borja, C. S. Peckham, A. De Ruiter, H. Lyall, and P. A. Tookey, “Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000–2006,” AIDS, vol. 22, no. 6, pp. 973–981, 2008.

[3] J. Warszawski, R. Tubiana, J. Le Chenadec et al., “Mother-to-child HIV transmission despite antiretroviral therapy in the ANRS French Perinatal Cohort,” AIDS, vol. 22, no. 2, pp. 289–299, 2008.

[4] E. R. Cooper, M. Charurat, D. N. Burns, W. Blattner, and R. Hoff, “Trends in antiretroviral therapy and mother-infant transmission of HIV,” Journal of Acquired Immune Deficiency Syndromes, vol. 24, no. 1, pp. 45–47, 2000.

[5] A. Dorenbbaum, C. K. Cunningham, R. D. Gelber et al., “Two-dose intrapartum/newborn nevirapine and standard antiretroviral therapy to reduce perinatal HIV transmission: a randomized trial,” Journal of the American Medical Association, vol. 288, no. 2, pp. 189–198, 2002.

[6] Antiretroviral-Pregnancy-Registry-Steering-Committee. Antiretroviral Pregnancy Registry International. Interim Report for 1 January 1989 through 31 July 2009, 2009, http://www.apregistry.com/.

[7] Company B-MS. Healthcare Provider Important Drug Warning Letter, 2001.

[8] J. Hitti, L. M. Frenkel, A. M. Stek et al., “Maternal toxicity with continuous nevirapine in pregnancy results from PACTG 1022,” Journal of Acquired Immune Deficiency Syndromes, vol. 36, no. 3, pp. 772–776, 2004.

[9] N. Kontorinis and D. T. Dieterich, “Toxicity of non-nucleoside analogue reverse transcriptase inhibitors,” Seminars in Liver Disease, vol. 23, no. 2, pp. 173–181, 2003.

[10] D. W. Ouyang, S. B. Brogly, M. Lu et al., “Lack of increased hepatotoxicity in HIV-infected pregnant women receiving nevirapine compared with other antiretrovirals,” AIDS, vol. 24, no. 1, pp. 109–114, 2010.

[11] D. W. Ouyang, D. E. Shapiro, M. Lu et al., “Increased risk of hepatotoxicity in HIV-infected pregnant women receiving antiretroviral therapy independent of nevirapine exposure,” AIDS, vol. 23, no. 18, pp. 2425–2430, 2009.

[12] A. F. Tarantal, M. L. Marthas, J. P. Shaw, K. Cundy, and N. Bischoffberger, “Administration of 9-[[2-(R)-(phosphonomethoxy)propyl]adenine (PMPA) to gravid and infant rhesus macaques (Macaca mulatta): safety and efficacy studies,” Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology, vol. 20, no. 4, pp. 323–333, 1999.

[13] K. K. A. Van Rompay, L. L. Brignolo, D. J. Meyer et al., “Biological effects of short-term or prolonged administration of 9-[[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques (Macaca mulatta): safety and efficacy studies,” Antimicrobial Agents and Chemotherapy, vol. 48, no. 5, pp. 1469–1487, 2004.

[14] A. M. Cotter, A. G. Garcia, M. L. Duthely, B. Luke, and M. J. O’Sullivan, “Is antiretroviral therapy during pregnancy associated with an increased risk of preterm delivery, low birth weight, or stillbirth?” Journal of Infectious Diseases, vol. 193, no. 9, pp. 1195–1201, 2006.

[15] D. K. Eokuve, P. A. Coffie, R. Becquet et al., “Antiretroviral therapy in pregnant women with advanced HIV disease and pregnancy outcomes in Abidjan, Côte d’Ivoire,” AIDS, vol. 22, no. 14, pp. 1815–1820, 2008.

[16] A. P. Kourtis, P. Bansil, M. McSheets, S. F. Meikle, S. F. Posner, and D. J. Jamieson, “Hospitalizations of pregnant HIV-infected women in the USA prior to and during the era of HAART, 1994–2003,” AIDS, vol. 20, no. 14, pp. 1823–1831, 2006.

[17] A. P. Kourtis, C. H. Schmid, D. J. Jamieson, and J. Lau, “Use of antiretroviral therapy in pregnant HIV-infected women and the risk of premature delivery: a meta-analysis,” AIDS, vol. 21, no. 5, pp. 607–615, 2007.

[18] R. E. Tuomala, D. E. Shapiro, L. M. Mofenson et al., “Antiretroviral therapy during pregnancy and the risk of an adverse outcome,” New England Journal of Medicine, vol. 346, no. 24, pp. 1863–1870, 2002.

[19] R. E. Tuomala, H. Watts, D. Li et al., “Improved obstetric outcomes and few maternal toxicities are associated with antiretroviral therapy, including highly active antiretroviral therapy during pregnancy,” Journal of Acquired Immune Deficiency Syndromes, vol. 38, no. 4, pp. 449–473, 2005.

[20] C. K. Cunningham, M. L. Chaix, C. Rekacewicz et al., “Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316,” Journal of Infectious Diseases, vol. 186, no. 2, pp. 181–188, 2002.

[21] A. S. Duran, M. H. Losso, H. Salomón et al., “Drug resistance among HIV-infected pregnant women receiving antiretrovirals for prophylaxis,” AIDS, vol. 21, no. 2, pp. 199–205, 2007.

[22] F. E. Lyons, S. Coughlan, C. M. Byrne, S. M. Hopkins, W. W. Hall, and F. M. Mulcahy, “Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy,” AIDS, vol. 19, no. 1, pp. 63–67, 2005.

[23] E. T. Overton, S. Sungkanuparph, D. Nurudinova, and W. G. Powderly, “Antiretroviral resistance among HIV-positive pregnant women who have antiretroviral experience from previous pregnancy,” AIDS, vol. 19, no. 13, p. 1439, 2005.

[24] A. Weinberg, J. Forster-Harwood, E. J. McFarland et al., “Resistance to antiretrovirals in HIV-infected pregnant women,” Journal of Clinical Virology, vol. 45, no. 1, pp. 39–42, 2009.

[25] A. Gingelmaier, J. Eberle, B. P. Kost et al., “Protease inhibitor-based antiretroviral prophylaxis during pregnancy and the development of drug resistance,” Clinical Infectious Diseases, vol. 50, no. 6, pp. 890–894, 2010.

[26] A. Weinberg, J. E. F. Harwood, E. J. McFarland et al., “Kinetics and determining factors of the virologic response to antiretrovirals during pregnancy,” Infectious Diseases in Obstetrics and Gynecology, vol. 2009, Article ID 621780, 2009.

[27] L. Mandelbrot, A. Landreau-Mascaro, C. Rekacewicz et al., “Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1,” Journal of the American Medical Association, vol. 285, no. 16, pp. 2083–2093, 2001.

[28] D. H. Watts, R. Balasubramanian, R. T. Maupin et al., “Maternal toxicity and pregnancy complications in human immunodeficiency virus-infected women receiving antiretroviral therapy: PACTG 316,” American Journal of Obstetrics and Gynecology, vol. 190, no. 2, pp. 506–516, 2004.

[29] S. Timmermans, C. Tempelman, M. H. Godfried et al., “Nelfinavir and nevirapine side effects during pregnancy,” AIDS, vol. 19, no. 8, pp. 795–799, 2005.
[30] E. M. Connor, R. S. Sperling, R. Gelber et al., “Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment,” New England Journal of Medicine, vol. 331, no. 18, pp. 1173–1180, 1994.
[31] W. H. Bae, C. Wester, L. M. Smeaton et al., “Hematologic and hepatic toxicities associated with antenatal and postnatal exposure to maternal highly active antiretroviral therapy among infants,” AIDS, vol. 22, no. 13, pp. 1633–1640, 2008.
[32] J. Le Chenadec, M. J. Mayaux, C. Guihenneuc-Jouyaux, and S. Blanche, “Perinatal antiretroviral treatment and hematopoiesis in HIV-uninfected infants,” AIDS, vol. 17, no. 14, pp. 2053–2061, 2003.
[33] M. M. Mussi-Pinhata, M. A. C. Rego, L. Freimanis et al., “Maternal antiretrovirals and hepatic enzyme, hematologic abnormalities among human immunodeficiency virus type 1-uninfected infants: the NISDI perinatal study,” Pediatric Infectious Disease Journal, vol. 26, no. 11, pp. 1032–1037, 2007.
[34] C. Foster, H. Lyall, B. Olmscheid, G. Pearce, S. Zhang, and D. M. Gibb, “Tenofovir disoproxil fumarate in pregnancy and prevention of mother-to-child transmission of HIV-1: is it time to move on from zidovudine?” HIV Medicine, vol. 10, no. 7, pp. 397–406, 2009.
[35] K. A. Lyseng-Williamson, N. A. Reynolds, and G. L. Plosker, “Tenofovir disoproxil fumarate: a review of its use in the management of HIV infection,” Drugs, vol. 65, no. 3, pp. 413–432, 2005.
[36] S. Mallal, D. Nolan, C. Witt et al., “Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir,” Lancet, vol. 359, no. 9308, pp. 727–732, 2002.
[37] P. Domingo, M. C. Cabeza, A. Pruvost et al., “Relationship between HIV/highly active antiretroviral therapy (HAART)-associated lipodystrophy syndrome and stavudine-triphosphate intracellular levels in patients with stavudine-based antiretroviral regimens,” Clinical Infectious Diseases, vol. 50, no. 7, pp. 1033–1040, 2010.
[38] M. Hurst and S. Noble, “Stavudine: an update of its use in the treatment of HIV infection,” Drugs, vol. 58, no. 5, pp. 919–949, 1999.
[39] B. H. Chi, A. Mwango, M. Giganti et al., “Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia,” Journal of Acquired Immune Deficiency Syndromes, vol. 54, no. 1, pp. 63–70, 2010.
[40] L. Elzi, C. Marzolini, H. Furrer et al., “Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008,” Archives of Internal Medicine, vol. 170, no. 1, pp. 57–65, 2010.
[41] S. L. Nightingale, “From the food and drug administration,” The Journal of the American Medical Association, vol. 280, no. 17, p. 1472, 1998.
[42] M. H. Davies, R. C. M. A. Da Silva, S. R. Jones, J. B. Weaver, and E. Elias, “Fetal mortality associated with cholestasis of pregnancy and the potential benefit of therapy with ursodeoxycholic acid,” Gut, vol. 37, no. 4, pp. 580–584, 1995.
[43] D. M. Paternoster, F. Fabris, G. Palù et al., “Intra-hepatic cholestasis of pregnancy in hepatitis C virus infection,” Acta Obstetricia et Gynecologica Scandinavica, vol. 81, no. 2, pp. 99–103, 2002.
[44] M. M. Saleh and K. R. Abdol, “Intrahepatic cholestasis of pregnancy: review of the literature and evaluation of current evidence,” Journal of Women’s Health, vol. 16, no. 6, pp. 833–841, 2007.
[45] D. Brites, C. M. P. Rodrigues, H. Van-Zeller, A. Brito, and R. Silva, “Relevance of serum bile acid profile in the diagnosis of intrahepatic cholestasis of pregnancy in an high incidence area: portugal,” European Journal of Obstetrics Gynecology and Reproductive Biology, vol. 80, no. 1, pp. 31–38, 1998.
[46] V. Soriano, M. Puoti, P. Garcia-Gascó et al., “Antiretroviral drugs and liver injury,” AIDS, vol. 22, no. 1, pp. 1–13, 2008.